世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
World Science and Technology-Modernization of Traditional Chinese Medicine
2015年
7期
1414-1418
,共5页
侯滔%丁辉%史丽颖%何牮%王纪霞%魏来%张秀莉%梁鑫淼
侯滔%丁輝%史麗穎%何牮%王紀霞%魏來%張秀莉%樑鑫淼
후도%정휘%사려영%하천%왕기하%위래%장수리%량흠묘
羟基茜草素%GPR35%激动剂%无标记细胞分析%靶点药理学
羥基茜草素%GPR35%激動劑%無標記細胞分析%靶點藥理學
간기천초소%GPR35%격동제%무표기세포분석%파점약이학
Purpurin%GPR35%agonist%label-free cellular assays%molecular pharmacology
目的:羟基茜草素为茜草的代表性成分,研究其作用的分子靶标对阐明茜草药效物质基础及作用机理具有重要意义。方法:本研究采用HT-29细胞培养,以其高表达的GPR35受体为靶标,通过无标记细胞靶点药理学技术检测羟基茜草素对GPR35受体的激动活性。结果:研究结果表明,羟基茜草素在HT-29细胞上能够引起DMR响应,且响应曲线类型与GPR35受体激动剂敏喘宁一致,其EC50值为6.142±0.189μmol·L-1。此外,在HT-29细胞上,羟基茜草素对GPR35受体激动剂敏喘宁有脱敏作用, GPR35受体拮抗剂ML145对羟基茜草素有拮抗作用。结论:由此可以推断羟基茜草素为GPR35受体的激动剂。
目的:羥基茜草素為茜草的代錶性成分,研究其作用的分子靶標對闡明茜草藥效物質基礎及作用機理具有重要意義。方法:本研究採用HT-29細胞培養,以其高錶達的GPR35受體為靶標,通過無標記細胞靶點藥理學技術檢測羥基茜草素對GPR35受體的激動活性。結果:研究結果錶明,羥基茜草素在HT-29細胞上能夠引起DMR響應,且響應麯線類型與GPR35受體激動劑敏喘寧一緻,其EC50值為6.142±0.189μmol·L-1。此外,在HT-29細胞上,羥基茜草素對GPR35受體激動劑敏喘寧有脫敏作用, GPR35受體拮抗劑ML145對羥基茜草素有拮抗作用。結論:由此可以推斷羥基茜草素為GPR35受體的激動劑。
목적:간기천초소위천초적대표성성분,연구기작용적분자파표대천명천초약효물질기출급작용궤리구유중요의의。방법:본연구채용HT-29세포배양,이기고표체적GPR35수체위파표,통과무표기세포파점약이학기술검측간기천초소대GPR35수체적격동활성。결과:연구결과표명,간기천초소재HT-29세포상능구인기DMR향응,차향응곡선류형여GPR35수체격동제민천저일치,기EC50치위6.142±0.189μmol·L-1。차외,재HT-29세포상,간기천초소대GPR35수체격동제민천저유탈민작용, GPR35수체길항제ML145대간기천초소유길항작용。결론:유차가이추단간기천초소위GPR35수체적격동제。
Purpurin is a common component ofRubia cordifolia L. The study on its molecular target was useful for elucidating the therapeutic material basis and action mechanism ofR. cordifolia. HT-29 cells were used in the cell culture. The highly expressed G Protein-coupled Receptor-35 (GPR35) agonist was used as target. The label-free optical biosensor cellular assay was used to investigate the agonist activity ofpurpurin at an endogenous receptor. The results showed thatpurpurin can cause DMR response in HT-29 cells. And the DMR response curve type was consistent with zaprinast. Its EC50 was 6.142± 0.189μmol·L-1. In addition,purpurinhad desensitization effect on GPR35 agonist zaprinast in HT-29 cells. GPR35 agonist ML145 blocked the DMR ofpurpurin. It was concluded thatpurpurinwas the GPR35 agonist.